Low-grade gliomas are a slow-growing but devastating type of brain cancer that significantly impacts the lives of patients, many of whom are young adults in their prime. Characterised by a specific mutation gene called IDH, current treatments are limited and LGG have long been considered incurable.
Thanks to the pioneering BrainPOP clinical trial program, led by The Brain Cancer Centre, this innovative approach involves collecting tumour samples before and after treatment, enabling researchers to learn exactly how therapies work within the brain.
They have been able to directly study how a new drug, Safusidenib, works inside the brain. This oral therapy targets the IDH1 gene mutation found in many LGGs.
https://mail.google.com/mail/u/0/#search/Sam+McGuane/FMfcgzQcpTJzjvnqkvhLXkgFKZxCTbCP
https://www.carriesbeanies4braincancer.com/our-story
